Brands, Generics and Hatch-Waxman: New Challenges; Unabated Controversy

24 June 2011 Washington, D.C. Past Event

Location

The Westin City Center
Washington, D.C.

Agenda

June 24, 2011
Foley Partner David Rosen will speak on biosimilars during the panel "Regulatory Strategies and Conundrums" at FDLI's Brands, Generics and Hatch-Waxman: New Challenges; Unabated Controversy conference.

Program Description:

The Drug Price Competition and Patent Term Restoration Act of 1984, known as the Hatch-Waxman Amendments, continues to be one of the most litigated and generally contentious arenas of drug law. The constant array of lawsuits, petitions, and administrative challenges regarding 180-day exclusivity, patent listings, and patent-term extensions have addressed important issues during the last year, resolving some, but further complicating others. This program will provide an in-depth analysis of these ongoing issues. The Program will also address antitrust considerations associated with Hatch-Waxman patent and administrative challenges and the interplay between Hatch-Waxman and the newly authorized biosimilars approval pathway.

Related Services

Insights

Brands, Generics and Hatch-Waxman: New Challenges; Unabated Controversy

Location

The Westin City Center
Washington, D.C.

Agenda

June 24, 2011